Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pregnant Pause: First Phase III Data Hint At Improved Success For ObsEva IVF Drug

Executive Summary

Top-line data for the IVF drug look promising but what investors really want to see are the Phase III data for ObsEva's lead product expected later this year in the much larger uterine fibroid market. 

Advertisement

Related Content

Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?
Takeda Paves The Way For Myovant With Phase III Fibroid Success
IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100479

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel